Author

T. Conley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Jones· 2 shared J. Ashton· 2 shared M. T. Milano· 2 shared N. Khazan· 2 shared R. K. Singh· 2 shared R. Moore· 2 shared R. Pandita· 2 shared V. Hovanesian· 2 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Jones

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 but controls THMYCN neuroblastoma growth PD-L1 independently

R. K. Singh, K. Kim, R. B. Rowswell-Turner, J. N. Hansen, N. Khazan, A. Jones, U. Sivagnanalingam, Y. Teramoto, T. Goto, Y. Jian, N. Battaglia, T. Conley, V. Hovanesian, N. Yano, R. Pandita, , R. Moore

This study shows that MeTC7, a VDR antagonist, reduces PD-L1 expression in cancer cells and inhibits neuroblastoma growth independently of PD-L1.

bioRxiv · Aug 16, 2020 · PreprintCancer Biology

Septins disruption controls tumor growth and enhances efficacy of Herceptin

R. K. Singh, K. K. Kim, N. Khazan, R. B. Rowswell_Turner, C. Laggner, A. Jones, P. Srivastava, V. Hovanesian, L. Lamere, T. Conley, R. Pandita, C. Baker, J. R. Myers, E. Prichett, A. Awada, , R. Moore

The paper develops UR214-9, a compound that disrupts septin filaments in cancer cells, inhibiting growth of HER2+ tumors and enhancing Herceptin efficacy.

bioRxiv · Feb 19, 2020 · PreprintCancer Biology